MINNEAPOLIS--(BUSINESS WIRE)--Uromedica, Inc. announces the initiation of its FDA Investigational Device Exemption trial for ACT® to evaluate its safety and efficacy for treatment of female SUI.

The adjustable continence therapy consisted of 2 silicone balloons that were surgically placed periurethrally at the bladder neck. In addition, a subcutaneous port was positioned between the labia ...

PLYMOUTH, Minn.--(BUSINESS WIRE)--Uromedica, Inc., today announced that it has successfully completed its first US commercial implant of ProACT™ Adjustable Continence Therapy for Men. The procedure ...

June 2, 2010 (San Francisco) – An investigational minimally invasive device, known as the Adjustable Continence Therapy (ACT, Uromedica, Inc.) system, seems to be an effective treatment for women with ...

Preliminary results from the North American Adjustable Continence Therapy (ACT) clinical study group will be presented at the annual meeting of the American Urological Association convened in Anaheim, ...

Uromedica, Inc. announces today that four new Category I CPT (Current Procedural Terminology) codes have been assigned to their FDA-approved product, ProACT™ Adjustable Continence Therapy for Men and ...

Since 2001, Uromedica has been selling its Adjustable Continence Therapy (ACT) for women and the ProACT for men internationally, and this year some of the products will debut in the United States.

Introduction and Objectives: The efficacy of adjuvant and salvage external beam radiation (AXRT+SXRT) for prostate cancer after radical prostatectomy (RP) has been debated because of the inability to ...